Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Biomarkers

Therapeutic area intelligence for Biomarkers with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
5
Catalysts
0
Companies
1

Companies

clinical laboratories →

Assets

Characterization →
Circular →
Establishment →
NDA021314 →

Recent signals(5)

RegulatoryJuly 30, 2026

FDA Approval Update for Meridian Bioscience's NDA021314

The FDA has accepted the application NDA021314 from Meridian Bioscience for review.

RegulatoryJuly 29, 2026

FDA Approval Update for Meridian Bioscience's NDA021314

The FDA has accepted the NDA021314 submission from Meridian Bioscience for review.

ClinicalJuly 16, 2026

Characterization of PI4K/PIPK Alterations in Solid Tumors for Biomarker Development

The study characterizes genomic alterations in PI4K and PIPK genes across solid tumors and their correlation with clinical outcomes.

ClinicalJuly 7, 2026

Circular RNAs as Potential Biomarkers in Cancer Diagnosis and Prognosis

Circular RNAs (circRNAs) are dysregulated in cancer and may serve as biomarkers for diagnosis and prognosis.

ClinicalJune 19, 2026

Establishment of Pulmonary Hypertension Biorepository for Future Biomarker Discovery

The NIH is establishing a biorepository for patients with Pulmonary Hypertension to discover novel biomarkers.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.